Meeting Banner
Abstract #0144

The Role of Iron Chelation in the Tumour Microenvironment of Triple-Negative Breast Cancer 

Paola Porcari1, Ellen Ackerstaff1, Dov P Winkleman1, Suresh Veeraperumal1, Natalia Kruchevsky1, H. Carl Lekaye1, and Jason A. Koutcher1,2,3,4
1Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 4Weill Cornell Medical College, Cornell University, New York, NY, United States

Intracellular iron, essential for cancer cell proliferation and metabolism, is modified in cancer cells. Triple-negative breast cancers are metastatic cancers associated with a high recurrence rate, poor prognosis and lack of effective targeted therapies. We are investigating the potential of Deferiprone, a clinically approved intracellular iron chelator for non-cancer related diseases, to improve chemotherapeutic treatment response in triple-negative breast cancer by altering iron-dependent proliferation and metabolism. The effectiveness of Deferiprone to impair triple-negative breast cancer cell growth and affect cellular metabolism was evaluated by monitoring live cells, exposed to Deferiprone, in an MR-compatible cell bioreactor using multi-nuclear MRS.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here